By: Jonathan Block
Phase 3 VIKTORIA-1 results show Revtorpyk beat Vijoice in advanced breast cancer PFS and response duration.
Jonathan Block is a Managing Editor at Seeking Alpha, where he focuses on finance and healthcare topics, including gene therapy, oncology, and digital health. With a Master of Public Health from CUNY Graduate School of Public Health, he brings expertise in pharmaceuticals and healthcare technology to his reporting. Jonathan has been featured in The National Law Review, NewsBreak, Defiance Crescent News, JD Supra, and Seeking Alpha.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Jonathan Block's coverage focuses on investment analysis, press releases, and data citations related to sales & marketing and automotive industries. He would likely be interested in pitches that provide in-depth analysis of stock performance, company news, and market trends within these sectors.
Given his focus on investment analysis and citation of data, Jonathan may find value in pitches from financial experts who can offer unique insights into the potential impact of various factors on stock performance or industry trends.
While Jonathan does not have a specific geographic focus mentioned but given the nature of his articles focusing mainly on companies listed in US stock exchanges (NASDAQ: HAS; NYSE: MTN), it is safe to assume he has an interest primarily in the US market.
This information evolves through artificial intelligence and human feedback. Improve this profile .